ReviewInternational journal of cardiology. Heart & vasculature2026
Cardiovascular impact of chronic venous disease: A systematic review and meta-analysis.
Review in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to gather and summarize evidence on the potential links between chronic venous disease (CVeD), cardiovascular events and mortality in adults. A systematic search of the PubMed database was conducted in accordance with PRISMA guidelines in October 2025. Observational studies or registries were eligible. Adults diagnosed with CVeD were compared with controls free of CVeD or varicose veins. Primary outcomes were cardiovascular events (angina, atrial fibrillation, chronic heart failure, coronary artery disease, deep vein thrombosis, stroke, myocardial infarction, peripheral artery disease, pulmonary embolism, transient ischaemic attack, composite of MACE) and all-cause mortality. Secondary outcomes focused on coronary artery and heart disease. Random-effects meta-analyses of time-to-event outcomes determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs). The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.